Background--Epicardial adipose tissue (EAT) is in immediate apposition to the underlying myocardium and, therefore, has the potential to influence myocardial systolic and diastolic function or myocardial geometry, through paracrine or compressive mechanical effects. We aimed to review the association between volumetric EAT and markers of myocardial function and geometry.
picardial adipose tissue (EAT) has been widely studied as a potential contributor to cardiovascular pathological characteristics. Much of this research has focused on its effect on coronary atherosclerosis, 1 but there are unique properties of EAT that may lead to an effect on myocardial function. EAT shares direct anatomic contact with the myocardium without fascial interruption 2 and, therefore, may exhibit local compressive forces, resulting in alteration of myocardial function and geometry. In addition, the shared blood supply of the coronary circulation to both the myocardium and surrounding EAT may predispose paracrine effects on the neighboring myocardium with such inflammatory cytokines as MCP-1 (monocyte chemoattractant), interleukin-b, interleukin-6, tumor necrosis factor-a, and leptin. 2 Persisting inflammation may lead to collagen deposition and subsequent impaired left ventricular (LV) relaxation and further effects on diastolic and systolic function. Furthermore, there is an association between EAT and release of free fatty acids, as well as their myocardial consumption. 3 The relationship between obesity, visceral fat, and EAT may also explain effects on myocardial function, chamber size, and mass. Several methods have been used for measurement of EAT, including echocardiography, cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI). Echocardiography may overestimate or underestimate total EAT volume because of single-plane assessment and the effects of probe angulation on linear measurement. Single-slice area measurements on CT or MRI are also limited by being only single-plane measures. Recently, we have demonstrated the superiority of volumetric EAT assessment in comparison to 2-dimensional linear echocardiographic EAT thickness. 4 We, therefore, sought the association of full-volume quantification of EAT (assessed by cardiac CT or cardiac MRI) with myocardial function, as assessed by transthoracic echocardiography, full R-R interval cardiac CT, or cardiac MRI.
Methods Search Method
We conducted this systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement, and the trial was registered with PROSPERO (CRD 42017038400). The search was conducted in MEDLINE, EMBASE, and PubMed databases, ending in March 2018. References of eligible articles were hand searched for additional articles. Searches were restricted to human studies, and conference abstracts were included. A study search flowchart is presented in Figure 1 , and the specific search term strategy is given in Table S1 . The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Our inclusion criteria were as follows: patients undergoing cardiac CT (CT angiography or calcium score) or MRI with volumetric assessment of EAT (either volume or mass), with cardiac imaging for assessment of myocardial function parameters (full cardiac cycle cardiac CT or MRI or echocardiography), or measurement of myocardial geometry (LV mass, LV volumes, and left atrium size) by validated methods. 
Clinical Perspective
What Is New?
• Increasing epicardial adipose tissue volume is associated with diastolic dysfunction, independent of other markers of adiposity.
• Epicardial adipose tissue is an effect modifier for left ventricle chamber geometry.
• Epicardial adipose tissue is not associated with systolic function.
What Are the Clinical Implications?
• Epicardial adipose tissue may represent an important target for therapy associated with diastolic dysfunction.
Assessment of diastolic function was restricted to studies using echocardiography. Exclusion criteria included the following: any study with linear measurement of EAT thickness, single-slice area measures of EAT, measures of myocardial lipid content not differentiated from EAT, and measurement of paracardial adipose tissue (ie, fat beyond the parietal pericardium). Two authors (N.N. and R.G.M.) independently reviewed the abstracts from the search to meet the inclusion criteria, and discrepancies were resolved by consensus. Probable overlap of the patient cohort with a similar study led to exclusion of the smaller study. 
Statistical Analysis
Data on univariable correlations are presented because this was the most consistent measure seen in included studies.
Where multivariable regression was performed, adjusted study estimates and model covariates are reported. Meta-analysis was performed for the weighted mean difference in EAT volume between groups with and without diastolic dysfunction. Metaregression of weighted mean difference as an effect size and the combined mean EAT in included studies were performed with the moment-based estimate of between-study variance and a permutation test using 1000 Monte Carlo simulations to moderate for potentially spurious results, as previously described. 6 Precision of pooled estimates is reported as 95% confidence intervals, and heterogeneity is reported by the I 2 statistic. The Newcastle Ottawa Scale was used to assess risk of bias (Tables S2 and S3 ). Statistical analysis was performed using StataMP 14.0 (StataCorpLP, College Station, TX).
Results

Study Selection
A brief outline summary of the 22 studies (18 published and 4 conference papers) included in this review is presented in Table 1 .
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Association of EAT With LV Diastolic Function
There were 11 studies that investigated the relationship between EAT and diastolic parameters, with 5 specifying adherence to an iteration of the American Society of Echocardiography diastolic guidelines. 29 Although some studies did perform comprehensive Doppler measures, such as isovolumic relaxation times, deceleration times, and pulmonary vein Doppler, the association with EAT individually with each parameter was not described. The classification of patients with diastolic dysfunction was available in 5 studies. Most patients (26%-38% of total cohort) had grade 1 diastolic dysfunction, with fewer qualifying as grade ≥2 (2%-28%).
In the 5 studies that measured differences in EAT between groups, EAT was significantly greater in the diastolic dysfunction group compared with patients with normal diastolic function (weighted mean difference, 24.4 mL; 95% confidence interval, 18.5-30.4 mL; P<0.001; I 2 =28%) ( Figure 2 in all but one study, no consistent association was seen with the E/A ratio (r value range, À0.40 to 0.08). Increasing EAT was an independent predictor of diastolic dysfunction, e 0 and E/e 0 independent of age, sex, and measures of adiposity (Table 2) . No independent association was identified with the E/A ratio. In 6 studies, hypertension was also an adjusted covariate in the model, and increasing EAT remained a predictor of altered diastolic parameters.
Association of EAT With Systolic Function
Of 10 studies describing the association of EAT with systolic parameters, LV function was evaluated with MRI in 5 and echocardiography in 4 (Table 3) . 3, 10, 11, 16, 18, 19, 22, 27 One study reported associations between EAT and global longitudinal strain, a subclinical measure of myocardial function. 24 Only one described an independent effect of EAT on LV ejection fraction (LVEF) by echocardiography. 19 No univariable correlation with LVEF was reported in the MRI studies. [10] [11] [12] Of the 6 studies reporting multivariable regression analysis, an independent association with LVEF was observed in 2 studies: one study was performed in patients with established coronary artery disease (CAD) stratified by LVEF and compared with normal controls (hazard ratio, 0.48; 95% confidence interval, 0.28-0.68; P<0.01), 11 and the other study was performed in patients undergoing investigation for suspected CAD with reduced LVEF compared with normal LVEF (values not reported). 19 The only consistent feature across all studies appeared to be a relative decrease in EAT as LVEF decreased. In studies that included control groups (ie, normal LVEF), no association of EAT with EF was identified in the control group. One study demonstrated a significant inverse correlation with EAT (normalized to LV mass) with cardiac output and stroke volume (but not LVEF) 3 In the study related to strain analysis, 24 there was a positive correlation with EAT and impaired 3-dimensional global longitudinal strain (r=0.601, P<0.001) that remained significant on multivariable regression (standardized b=0.512, P<0.001), independent of markers of obesity and diabetes mellitus.
Association of EAT With Chamber Measures
There were 14 studies with data relating to a measure of myocardial geometry. All modalities of echocardiography, CT, and MRI were represented, with most values indexed to body surface area, unless otherwise specified. Some studies avoided indexation because body weight or other adiposity measures were used in regression models and, therefore, raw measures were used to prevent collinearity. The most often reported univariable correlation coefficient was for EAT and LV mass or indexed mass and was always (Table 4) .* An inconsistent association was seen with measures of adiposity in relation to EAT and cardiac structure. In patients with reduced LVEF, indexed EAT appears to be associated with indexed LV end-diastolic mass independent of BMI ( Table 4) . [10] [11] [12] One study assessing patients with suspected CAD and normal LVEF demonstrated that EAT correlated best with LV mass (nonindexed) in the nonobese cohort only (b=0.23, P<0.001). 8 Finally, in 2 observational studies, an independent association of EAT with LV mass (nonindexed), adjusted for body weight, was only seen in women (Table 4) .
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Discussion
This review of 21 studies has demonstrated the emerging body of work relating EAT to myocardial structure and function. Increasing EAT is associated with the following: (1) an increasing prevalence of diastolic dysfunction; (2) a concomitant increase in LV mass; and (3) no consistent association with markers of systolic function. However, these adipose tissue (EAT) volume on the weighted mean difference (effect size) of EAT in patients with and without diastolic dysfunction. Meta-regression bubble plot depicts increasing differences in mean EAT volume in patients with diastolic dysfunction as EAT increases. Circles represent the weight of each study. b coefficient is from meta-regression with associated SEE; P value is from Monte-Carlo testing (1000 simulations) and demonstrates a significant association (P=0.001).
correlations were no more than moderate; no coefficient exceeded 0.50.
Protective Functions of EAT
EAT has a high fatty acid content and can both release and scavenge excess free fatty acids to regulate myocardial energy production. 2 In addition, EAT secretes anti-inflammatory cytokines, such as adiponectin, adrenomedullin, and omentin, which have antiatherogenic effects; EAT also regulates vascular tone and cardiac remodelling. 33 There is a thermogenic role for EAT in providing heat for the myocardium in times of hypoxic or ischemic stress. 33 However, the presence of numerous proinflammatory Values are meanAESD or r value correlation coefficients, unless otherwise stated. BMI indicates body mass index; CAD, coronary artery disease; CO, cardiac output; DCM, dilated cardiomyopathy; EAT, epicardial adipose tissue; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LGE%, percentage of late gadolinium enhancement; LV, left ventricular; LV-EDD, LV end-diastolic diameter; LV-EDVI, LV end-diastolic volume index; LV-ESVI, left ventricular end-systolic volume index; LVRI, LV remodeling index; MRI, magnetic resonance imaging; NYHA, New York Heart Association; SV, stroke volume; VAT, visceral adipose tissue. *P<0.05. cytokines within EAT may lead to a potential imbalance of harmful versus protective cytokines and disruption of myocardial function. Higher levels of these molecules (eg, tumor necrosis factor-a, interleukin-6, interleukin-1, and MCP-1) are seen in patients with CAD or heart failure. It is uncertain whether the trigger for the imbalance of cytokines is a cause of the pathological characteristics or a consequence, and a potential reciprocal or bidirectional role has been proposed. 2 
EAT and Diastolic Dysfunction
Adipose tissue can modulate the cardiovascular system by mechanisms including sympathetic activation, adipokine secretion, and myocardial oxidative stress. 34, 35 EAT is regarded as a visceral fat depot. Visceral fat is metabolically active and is a determinant of diastolic function. 36 The adipokines within EAT can all affect diastolic function through persistent inflammation and subsequent collagen turnover, 37 impaired microvascular relaxation, or a direct toxic effect on the myocardium. 38, 39 The loss of protective effects of adiponectin can also modify diastolic function. 40 Mechanical effects may arise from myocardial compression of EAT because it lies within a fixed pericardial sac, 17 inducing a similar mechanism as pericardial constriction. Hachiya et al demonstrated an independent correlation of EAT with aortic pulse pressure as another mechanism of diastolic dysfunction that may be mediated by the association of EAT with aortic stiffness and, therefore, increased pulse wave velocity and early wave reflection. 18 Increased pressure in late systole may cause slower LV relaxation and subsequent diastolic dysfunction, as well as compromise coronary perfusion, especially if there is underlying CAD leading to impaired LV relaxation. 41 EAT is associated with obesity, which itself is independently associated with diastolic dysfunction. 42 Obese patients often have elevated EAT volumes, 17 and indexed EAT has modest incremental value for diastolic dysfunction over traditional covariates, such as metabolic syndrome, subclinical CAD, and LV mass index. 9 Although the results from our analysis demonstrate that EAT had an independent effect on diastolic function parameters over adiposity measures, adiposity measures varied considerably and included BMI, bioimpedence testing, area of visceral adipose tissue or subcutaneous adipose tissue, or indexed EAT, which accounts for body weight. This heterogeneity needs further explanation to adequately isolate the effect of obesity and EAT on diastolic function. The lack of an association of EAT with E/A ratio may be confounded by the effects of age, proportion of patients with CAD, measurement in patients with normal LVEF, and the U-shaped relationship of E/A ratio with diastolic function that makes it difficult to assess without the addition of other variables. 43 The evaluation of diastolic function is challenging and influenced by a patient's filling status, the presence of CAD, diabetes mellitus, obesity, as well as "normal" changes seen in the ageing patient. Although most studies aim to account for these factors in multivariable regression models, no more than association can be interpreted, and causality cannot be proved. Statistically, there may be implications of collinearity of obesity measures and EAT in multivariable models.
EAT and Systolic Dysfunction
Our study noted weak and inconsistent associations of EAT and systolic parameters. In the single study that evaluated EAT and longitudinal strain as a marker of subclinical myocardial dysfunction, there was a strong association noted independent of confounders, such as obesity and diabetes mellitus. 24 This is a notable finding; however, causality remains unproved and requires further assessment in larger-scale studies as a possible marker of the syndrome of heart failure with preserved ejection fraction. Various hypotheses have been developed to relate EAT and systolic function. In studies of patients with ischemic and dilated cardiomyopathy, there has been a consistent signal of reducing EAT with reducing LVEF, with less EAT also seen compared with normal controls or those with normal LVEF. [10] [11] [12] 19 As myocardium becomes progressively dysfunctional, the role of EAT as a source of energy or cytokine homeostasis may become less necessary, contributing to EAT depletion. Conversely, in obese patients, there was no association with EAT (normalized to cardiac mass) and LVEF, and there was a negative correlation with MRI-derived cardiac output as EAT increased. 3 The proposed mechanism is from mechanical restriction of myocardial expansion from EAT in diastole that may lead to less ventricular filling and, therefore, reduced cardiac output. 3 A further mechanism may involve the effects of a direct cytokine release, as seen in patients with decompensated heart failure, but no studies have applied this in the context of EAT volume.
EAT and Chamber Measures
Postmortem and experimental studies 44, 45 have demonstrated a constant ratio of epicardial fat/ventricular myocardium, regardless of underlying pathological characteristics of hypertrophy, ischemia, or normal muscle. Furthermore, the increase in fat mass parallels LV hypertrophy, although healthy controls have higher quantities of EAT. 10 Similar findings are seen when evaluating the LV remodeling index (ratio of mass/end-diastolic volume), where an inverse correlation is noted with LVEF and the EAT/LV remodeling index ratio. LVEF is inversely correlated with EAT and linearly correlated with LV remodeling index, suggesting that remodeling is not compensated by an adequate increase in EAT. 10 Obesity has shown a positive relationship with increased LV mass and EAT, yet the impact of obesity on myocardial SYSTEMATIC REVIEW AND META-ANALYSIS geometry may outweigh the local effects of ectopic fat because associations attenuated after adjustment for other adiposity measures, including body weight. 17 From a mechanistic perspective, the association of EAT with central obesity and visceral adipose tissue might result in greater LV afterload and subsequent increased LV output, therefore leading to LV remodeling. 8 As LV remodeling progresses, LV diameter, volume, and mass increase, which may then deplete EAT stores 12 and result in a vicious cycle of reduced protective benefits on the heart and further dysfunction. However, the independent association of EAT with LV mass is limited to nonobese subjects. 8 Associations of EAT with the incidence of CAD have been described in nonobese people 46 and could contribute to the so-called obesity paradox. 47 
Limitations
We acknowledge several limitations in our study. EAT measurement by different modalities may lead to differences between studies. Some reported EAT indexed to Body Surface Area (BSA) (therefore accounting for weight), and some reported raw values using weight as a covariate in multivariable models. Such normalization, as opposed to normalization to height, may obscure the contribution of obesity to differences in chamber volumes and mass, which are associated with EAT. Not all studies adjusted for hypertension in multivariable models, which is also associated with obesity and diastolic function. Variations in the reference literature on measures of diastolic function also lead to difficulties with comparing studies. The differences in regional location of EAT were not available in most studies and, therefore, the effect of EAT distribution was not assessable. The level of heterogeneity and variable study end points precluded detailed meta-analysis.
Conclusions
Despite small and heterogeneous studies, there is clear evidence of a consistent effect of volumetric EAT on myocardial diastolic function and chamber measurements; however, robust data are lacking to make causal inferences. These findings are observed despite adjustment for common confounders, such as adiposity. No consistent effect is seen with respect to systolic parameters. Further longitudinal studies are necessary to generate quantitative summary measures as well as develop potential targets for treatment.
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